The Cambridge Structural Database (CSD) was searched through two 3D queries based on substructures shared by well-known antagonists at the A1 and A3 adenosine receptors (ARs). Among the resulting 557 hits found in the CSD, we selected five compounds to purchase, synthesize, or translate synthetically into analogues better tailored to interact with the biological targets. Binding experiments using human ARs showed that four out of five tested compounds turned out to be antagonists at the A1AR or A 3AR with Ki values between 50 and 440 nM. Lead optimizations of 2-(benzimidazol-2-yl)quinoxalines (BIQs, 3) gave the best results in terms of potency and selectivity at the A1 and A 3 ARs. Particularly, 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline (3e) exhibited Ki values at the A1AR, A2AAR, and A3AR of 0.5, 3440, and 955 nM, respectively, whereas 2-(4-methylbenzimidazol-2-yl)quinoxaline (3b) displayed at the same ARs K i values of 8000, 833, and 26 nM, respectively.
|Autori:||NOVELLINO E.; COSIMELLI B.; EHLARDO M.; GRECO G.; IADANZA M.; LAVECCHIA A.; RIMOLI M.G.; SALA A.; DA SETTIMO A.; PRIMOFIORE G.; DA SETTIMO F.; TALIANI S.; LA MOTTA C.; KLOTZ K.N.; TUSCANO D.; TRINCAVELLI M.L.; MARTINI C.|
|Titolo:||2-(Benzimidazol-2-yl)quinoxalines: A Novel Class of selective Antagonists at Human A1 and A3 Adenosine Receptors Designed by 3D Database Searching|
|Anno del prodotto:||2005|
|Digital Object Identifier (DOI):||10.1021/jm050792d|
|Appare nelle tipologie:||1.1 Articolo in rivista|